Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06284798
Status:
RECRUITING
Last Update Posted:
2024-02-29
First Post:
2024-02-22
Brief Title:
A Research Study of a New Medicine NNC0650-0013 in Healthy Men
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
A First Human Dose Study Investigating Safety Tolerability and Pharmacokinetics of Subcutaneous Single Ascending Doses of NNC0650-0013 in Healthy Male Participants
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is testing a new study medicine which may be used to treat people with type 2 diabetes NNC0650-0013 is a new medicine which cannot be prescribed by doctors The purpose of the study is to see if the new study medicine is safe and how it works in participants body Participants will get a single dose of the study medicine either as injections under the skin or into a vein The injection will be given by the study staff If participants are chosen to get the study medicine as injections under the skin participants will either get NNC0650-0013 or placebo a dummy medicine without any active ingredients Which treatment participants get is decided by chance Participants will be required to fast overnight 3 times during the study The study will last between 11 and 17 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-506134-79 | OTHER | None | None |
| U1111-1291-7535 | OTHER | World Health Organization WHO | None |